ZBTB10

Summary

ZBTB10 (zinc finger and BTB domain containing 10, HGNC:30953) is a protein-coding gene on chromosome 8q21.13, encoding Zinc finger and BTB domain-containing protein 10 (Q96DT7). May be involved in transcriptional regulation.

Enables telomeric DNA binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II. Located in chromosome, telomeric region and nucleoplasm.

Source: NCBI Gene 65986 — RefSeq curated summary.

At a glance

• GWAS associations: 42
• Clinical variants (ClinVar): 127 total
• Druggable target: yes
• MANE Select transcript: NM_001105539

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30953
Approved symbol	ZBTB10
Name	zinc finger and BTB domain containing 10
Location	8q21.13
Locus type	gene with protein product
Status	Approved
Aliases	RINZF, FLJ12752
Ensembl gene	ENSG00000205189
Ensembl biotype	protein_coding
OMIM	618576
Entrez	65986

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000379091, ENST00000426744, ENST00000430430, ENST00000455036, ENST00000961791, ENST00000961792, ENST00000961793, ENST00000961794

RefSeq mRNA: 3 — MANE Select: NM_001105539 NM_001105539, NM_001277145, NM_023929

CCDS: CCDS47880, CCDS64920

Canonical transcript exons

ENST00000455036 — 6 exons

Exon	Start	End
ENSE00001479728	80518782	80518954
ENSE00001479730	80518403	80518579
ENSE00001479731	80513910	80514008
ENSE00001479734	80499494	80500382
ENSE00001523703	80519223	80526265
ENSE00003843299	80486226	80487782

Expression profiles

Bgee: expression breadth ubiquitous, 264 present calls, max score 94.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.9755 / max 845.1048, expressed in 1670 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
89523	6.0066	1501
89519	3.0651	496
89520	1.9566	447
89521	1.5659	425
89528	1.3585	466
89524	0.6827	400
89525	0.6009	303
89529	0.3428	138
89527	0.1631	69
89526	0.1324	61

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	94.56	gold quality
cauda epididymis	UBERON:0004360	93.53	gold quality
mucosa of paranasal sinus	UBERON:0005030	93.26	gold quality
corpus epididymis	UBERON:0004359	92.79	gold quality
cartilage tissue	UBERON:0002418	92.42	gold quality
calcaneal tendon	UBERON:0003701	92.30	gold quality
germinal epithelium of ovary	UBERON:0001304	92.20	gold quality
pigmented layer of retina	UBERON:0001782	92.09	gold quality
caput epididymis	UBERON:0004358	91.55	gold quality
oocyte	CL:0000023	90.82	gold quality
adrenal tissue	UBERON:0018303	90.80	gold quality
saphenous vein	UBERON:0007318	90.62	gold quality
placenta	UBERON:0001987	90.52	gold quality
endometrium	UBERON:0001295	90.25	gold quality
heart right ventricle	UBERON:0002080	90.04	gold quality
parietal pleura	UBERON:0002400	89.94	gold quality
ventricular zone	UBERON:0003053	89.70	gold quality
bronchial epithelial cell	CL:0002328	89.38	gold quality
mammary duct	UBERON:0001765	89.04	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	88.94	gold quality
urethra	UBERON:0000057	88.74	gold quality
superficial temporal artery	UBERON:0001614	88.72	gold quality
vena cava	UBERON:0004087	88.68	gold quality
ganglionic eminence	UBERON:0004023	88.67	gold quality
mucosa of sigmoid colon	UBERON:0004993	88.63	gold quality
tibia	UBERON:0000979	88.47	gold quality
synovial joint	UBERON:0002217	88.25	gold quality
colonic mucosa	UBERON:0000317	87.94	gold quality
pleura	UBERON:0000977	87.69	gold quality
visceral pleura	UBERON:0002401	87.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.55

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
ESR1
SP3

Upstream regulators (CollecTRI, top): SP1, SP3, SP4

miRNA regulators (miRDB)

346 targeting ZBTB10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-433-3P	99.98	69.37	1203

Literature-anchored findings (GeneRIF, showing 8)

• Study show that miR-27a indirectly regulates E2-responsiveness in MCF-7 cells through suppression of ZBTB10, thereby enhancing expression of ERalpha. (PMID:20382698)
• Collectively, these results indicated that stimulation of ovarian cancer cell VEGF, Cox2 and survivin expression by FSH involves the microRNA27a: ZBTB10-specificity protein pathway. (PMID:23254909)
• Sp1, Sp3, and Sp4 and Sp-regulated genes were downregulated by curcuminoids in SW-480 and this was accompanied by suppression of microRNA-27a (miR-27a) and induction of ZBTB10, an mRNA target of miR-27a and a transcriptional repressor of Sp expression. (PMID:23471840)
• ZBTB10 co-localizes with a subset of telomeres in ALT-positive U2OS cells and interacts with TRF2/RAP1 via the N-terminal region of TRF2. Our data establishes ZBTB10 as a novel variant repeat binding protein at ALT telomeres. (PMID:30629181)
• Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency. (PMID:35306527)
• MiR-361-5p promotes proliferation and inhibits apoptosis of fibroblast-like synoviocytes via targeting ZBTB10 in rheumatoid arthritis. (PMID:35608340)
• Structural insights into the recognition of telomeric variant repeat TTGGGG by broad-complex, tramtrack and bric-a-brac - zinc finger protein ZBTB10. (PMID:36657642)
• Intermittent Hypoxia Promotes TAM-Induced Glycolysis in Laryngeal Cancer Cells via Regulation of HK1 Expression through Activation of ZBTB10. (PMID:37834257)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zbtb10	ENSDARG00000077101
mus_musculus	Zbtb10	ENSMUSG00000069114
rattus_norvegicus	Zbtb10	ENSRNOG00000061862

Paralogs (5): ZBTB8A (ENSG00000160062), ZBTB9 (ENSG00000213588), ZBTB22 (ENSG00000236104), C17orf113 (ENSG00000267221), ZBTB8B (ENSG00000273274)

Protein

Protein identifiers

Zinc finger and BTB domain-containing protein 10 — Q96DT7 (reviewed: Q96DT7)

Alternative names: Zinc finger protein RIN ZF

All UniProt accessions (1): Q96DT7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96DT7-1	1	yes
Q96DT7-2	2
Q96DT7-3	3
Q96DT7-4	4

RefSeq proteins (3): NP_001099009, NP_001264074, NP_076418 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050457	ZnFinger_BTB_dom_contain	Family

Pfam: PF00651

UniProt features (43 total): cross-link 9, compositionally biased region 7, splice variant 4, strand 4, modified residue 3, sequence conflict 3, helix 3, region of interest 3, zinc finger region 2, sequence variant 2, chain 1, domain 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8GN3	X-RAY DIFFRACTION	1.8
8GN4	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DT7-F1	49.46	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 126, 210, 565, 245, 468, 483, 497, 573, 672, 684, 696, 706

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 296 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, ATACCTC_MIR202, MODULE_453, AGTCTTA_MIR499, IRF7_01, ONKEN_UVEAL_MELANOMA_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, AAACCAC_MIR140, MYCMAX_01, BLALOCK_ALZHEIMERS_DISEASE_UP, WTGAAAT_UNKNOWN, HP1SITEFACTOR_Q6, OCT1_06, OCT1_07, NELSON_RESPONSE_TO_ANDROGEN_UP

GO Biological Process (2): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (7): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), telomeric repeat DNA binding (GO:0042162), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): chromosome, telomeric region (GO:0000781), nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
transcription cis-regulatory region binding	1
negative regulation of transcription by RNA polymerase II	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transition metal ion binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
chromosomal region	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

948 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZBTB10	BRCA1	P38398	434
ZBTB10	CCL27	Q9Y4X3	423
ZBTB10	BEND3	Q5T5X7	423
ZBTB10	DEXI	O95424	408
ZBTB10	MORC3	Q14149	391
ZBTB10	MDC1	Q14676	387
ZBTB10	BTBD10	Q9BSF8	380
ZBTB10	TPD52	P55327	373
ZBTB10	ETV6	P41212	343
ZBTB10	ZBTB4	Q9P1Z0	316
ZBTB10	CDHR3	Q6ZTQ4	314
ZBTB10	PHB1	P35232	314
ZBTB10	CLEC16A	Q2KHT3	308
ZBTB10	ZNF18	P17022	284
ZBTB10	NAIF1	Q69YI7	284

IntAct

119 interactions, top by confidence:

A	B	Type	Score
PDLIM7	BAG3	psi-mi:“MI:0914”(association)	0.800
FBXL17	SKP1	psi-mi:“MI:0914”(association)	0.790
FBXL17	BACH1	psi-mi:“MI:0914”(association)	0.730
RHPN1	PODXL	psi-mi:“MI:0914”(association)	0.690
ZBTB10	MOB3C	psi-mi:“MI:0915”(physical association)	0.670
MOB3C	ZBTB10	psi-mi:“MI:0915”(physical association)	0.670
FOXK2	DVL2	psi-mi:“MI:0914”(association)	0.640
ZNF576	ZBED1	psi-mi:“MI:0914”(association)	0.640
IPO8	TRIM28	psi-mi:“MI:0914”(association)	0.640
CHCHD4	SSNA1	psi-mi:“MI:0914”(association)	0.640
MORF4L2	ZBTB10	psi-mi:“MI:0915”(physical association)	0.560
ZNF417	ZBTB10	psi-mi:“MI:0915”(physical association)	0.560
MORF4L1	ZBTB10	psi-mi:“MI:0915”(physical association)	0.560
ZBTB10	LSM4	psi-mi:“MI:0915”(physical association)	0.560
ZBTB10	MORF4L2	psi-mi:“MI:0915”(physical association)	0.560
ZBTB10	ZNF417	psi-mi:“MI:0915”(physical association)	0.560
LSM4	ZBTB10	psi-mi:“MI:0915”(physical association)	0.560
ZBTB10	MORF4L1	psi-mi:“MI:0915”(physical association)	0.560
ZNF169	ZNF316	psi-mi:“MI:0914”(association)	0.530
XAGE1A	THAP12	psi-mi:“MI:0914”(association)	0.530
PRICKLE3	SIAH2	psi-mi:“MI:0914”(association)	0.530
LACC1	DUSP14	psi-mi:“MI:0914”(association)	0.530

BioGRID (188): ZBTB10 (Two-hybrid), ZBTB10 (Two-hybrid), ZBTB10 (Two-hybrid), ZNF417 (Two-hybrid), MOB3C (Two-hybrid), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS)

ESM2 similar proteins: A0JN76, A1L2U9, B1WAZ8, B1WBU4, O15060, O35260, O43298, O93567, P14404, P41182, P41183, Q05516, Q0IH98, Q0IJ29, Q0P4X6, Q0V8G8, Q0VCJ6, Q15916, Q1L8W0, Q3B725, Q3SWU4, Q5TC79, Q5ZM39, Q6NRM8, Q6P882, Q6YND2, Q7TQG0, Q7TSZ8, Q7ZWZ4, Q801P1, Q80X44, Q86UZ6, Q8BID6, Q8CII0, Q8K088, Q8K0L9, Q8N680, Q8NAP8, Q8NCN2, Q8NCP5

Diamond homologs: A0JN76, A1L2U9, A1YEX3, A1YPR0, A2AAX3, B1WAZ8, B1WBS3, B1WBU4, B2RXF5, D3ZA50, O14867, O15062, O15156, O15209, O43167, O43298, O43829, O88282, O88939, O93567, O95365, P24278, P41182, P41183, P52739, P97302, P97303, Q08376, Q0IH98, Q0IJ29, Q0P4X6, Q0VCJ6, Q13105, Q14526, Q1H9T6, Q1L8W0, Q2T9Z7, Q3B725, Q3B7N9, Q3SWU4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 142 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	7	21.3×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

127 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	112
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

794 predictions. Top by Δscore:

Variant	Effect	Δscore
8:80499489:TACA:T	acceptor_loss	1.0000
8:80499493:G:A	acceptor_loss	1.0000
8:80499493:GGA:G	acceptor_gain	1.0000
8:80513906:TCAG:T	acceptor_loss	1.0000
8:80513907:CA:C	acceptor_loss	1.0000
8:80513908:A:AG	acceptor_gain	1.0000
8:80513908:AG:A	acceptor_loss	1.0000
8:80513909:G:GG	acceptor_gain	1.0000
8:80518397:TACTA:T	acceptor_loss	1.0000
8:80518399:CTAGG:C	acceptor_loss	1.0000
8:80518400:TAGG:T	acceptor_loss	1.0000
8:80518401:A:AT	acceptor_loss	1.0000
8:80518402:G:GT	acceptor_loss	1.0000
8:80499486:A:AG	acceptor_gain	0.9900
8:80499487:A:G	acceptor_gain	0.9900
8:80499488:TTACA:T	acceptor_loss	0.9900
8:80499492:A:AG	acceptor_gain	0.9900
8:80499492:AG:A	acceptor_gain	0.9900
8:80499493:G:GG	acceptor_gain	0.9900
8:80499493:GG:G	acceptor_gain	0.9900
8:80499493:GGAGT:G	acceptor_gain	0.9900
8:80500373:G:GT	donor_gain	0.9900
8:80500379:CCAGG:C	donor_loss	0.9900
8:80500380:CAGGT:C	donor_loss	0.9900
8:80500381:AGGTA:A	donor_loss	0.9900
8:80500382:GGT:G	donor_loss	0.9900
8:80500383:G:C	donor_loss	0.9900
8:80500384:T:A	donor_loss	0.9900
8:80513909:GATTT:G	acceptor_gain	0.9900
8:80514006:CTG:C	donor_loss	0.9900

AlphaMissense

5725 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:80518814:T:C	C724R	1.000
8:80518816:C:G	C724W	1.000
8:80518824:G:A	C727Y	1.000
8:80518825:T:G	C727W	1.000
8:80518836:C:A	A731D	1.000
8:80518854:T:C	L737P	1.000
8:80518860:G:T	R739M	1.000
8:80518861:G:C	R739S	1.000
8:80518861:G:T	R739S	1.000
8:80518862:C:A	H740N	1.000
8:80518862:C:G	H740D	1.000
8:80518864:C:A	H740Q	1.000
8:80518864:C:G	H740Q	1.000
8:80518892:T:C	F750L	1.000
8:80518894:T:A	F750L	1.000
8:80518894:T:G	F750L	1.000
8:80518898:T:C	C752R	1.000
8:80518899:G:A	C752Y	1.000
8:80518900:T:G	C752W	1.000
8:80518907:T:C	C755R	1.000
8:80518908:G:A	C755Y	1.000
8:80518909:T:G	C755W	1.000
8:80518919:T:A	F759I	1.000
8:80518919:T:C	F759L	1.000
8:80518920:T:C	F759S	1.000
8:80518920:T:G	F759C	1.000
8:80518921:T:A	F759L	1.000
8:80518921:T:G	F759L	1.000
8:80518931:G:A	E763K	1.000
8:80518932:A:T	E763V	1.000

dbSNP variants (sampled 300 via entrez): RS1000001226 (8:80486517 GC>G), RS1000049988 (8:80510840 C>A), RS1000062502 (8:80495994 GT>G), RS1000092294 (8:80489981 T>A), RS1000132366 (8:80497277 C>A), RS1000245687 (8:80488667 A>G), RS1000297707 (8:80488432 C>T), RS1000354177 (8:80507145 T>C), RS1000364412 (8:80485175 T>C), RS1000508612 (8:80500619 T>C), RS1000647268 (8:80522035 G>A), RS1000787349 (8:80507409 G>A), RS1000848921 (8:80503749 C>G), RS1000852356 (8:80493505 G>T), RS1000881056 (8:80487556 C>G,T)

Disease associations

OMIM: gene MIM:618576 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

42 associations (top):

Study	Trait	p-value
GCST001363_4	Atopic dermatitis	1.000000e-06
GCST001474_11	Hypothyroidism	4.000000e-06
GCST001612_20	Sex hormone-binding globulin levels	3.000000e-09
GCST001612_4	Sex hormone-binding globulin levels	7.000000e-08
GCST002083_23	Self-reported allergy	8.000000e-08
GCST002322_9	Asthma and hay fever	4.000000e-09
GCST002783_291	Body mass index	2.000000e-07
GCST002783_547	Body mass index	1.000000e-07
GCST002783_59	Body mass index	4.000000e-08
GCST003184_14	Atopic dermatitis	5.000000e-18
GCST003184_6	Atopic dermatitis	2.000000e-16
GCST003251_11	Late-onset myasthenia gravis	9.000000e-10
GCST003726_25	Basal cell carcinoma	9.000000e-11
GCST003987_14	Asthma	1.000000e-11
GCST003990_20	Allergy	1.000000e-09
GCST004904_79	Body mass index	1.000000e-13
GCST005038_70	Allergic disease (asthma, hay fever or eczema)	4.000000e-20
GCST005212_33	Asthma	1.000000e-10
GCST006409_23	Allergic rhinitis	2.000000e-10
GCST006810_8	Self-reported risk-taking behaviour	6.000000e-10
GCST006811_4	Body mass index	2.000000e-09
GCST006862_8	Asthma	2.000000e-08
GCST006979_465	Heel bone mineral density	7.000000e-11
GCST007325_277	General risk tolerance (MTAG)	5.000000e-13
GCST007564_18	Asthma or allergic disease (pleiotropy)	2.000000e-09
GCST007798_85	Asthma	3.000000e-24
GCST007798_86	Asthma	6.000000e-24
GCST007799_21	Asthma (adult onset)	4.000000e-16
GCST007800_10	Asthma (childhood onset)	2.000000e-30
GCST007993_23	Asthma (adult onset)	9.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004696	sex hormone-binding globulin measurement
EFO:0004340	body mass index
EFO:0008579	risk-taking behaviour
EFO:0009270	heel bone mineral density
EFO:1002011	adult onset asthma
EFO:0007778	urinary albumin to creatinine ratio
EFO:0004348	hematocrit
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5069372 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

62 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, increases expression, affects cotreatment	8
sodium arsenite	decreases expression, increases expression	3
Nickel	increases expression, decreases expression	3
Quercetin	affects cotreatment, decreases reaction, increases expression, decreases expression	3
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
Metribolone	increases expression	2
Cyclosporine	increases expression	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases expression, increases methylation	1
geraniol	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
trichostatin A	decreases expression	1
hyperoside	increases expression, decreases expression, affects cotreatment, decreases reaction	1
potassium chromate(VI)	increases expression	1
nickel sulfate	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
avobenzone	increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases expression	1
pentabromodiphenyl ether	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
ON 01910	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5059505	Binding	Proteomics fold change data (SUDHL4 cells, 1h)	Data for DCP probe CCT369260

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XV85	HEK293 eGFP-ZBTB10	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.